Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 16/20 | 0.45 |
| ▸ | TAS2R14 | Q9NYV8 | 2/20 | 0.44 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14890360 | 0.84 | SYK (0.47) | SYK | |
| SCHEMBL14890712 | 0.84 | SYK (0.64) | SYK | |
| Hydrochloric Acid SCHEMBL14890172 | 0.83 | SYK (0.63) | SYK | |
| SCHEMBL2984792 | 0.79 | MEN1 (0.51) | SYK | |
| SCHEMBL14890945 | 0.77 | SYK (0.74) | SYK | |
| SCHEMBL14890558 | 0.76 | SYK (0.74) | SYK | |
| SCHEMBL14890585 | 0.76 | SYK (0.44) | SYK | |
| SCHEMBL3016766 | 0.75 | SYK (0.38) | SYK | |
| SCHEMBL14890252 | 0.75 | SYK (0.75) | SYK | |
| SCHEMBL14890521 | 0.72 | SYK (0.70) | SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9169259-B2 | Imidazopyridazine compounds | HOFFMANN-LA ROCHE INC. (US) | 2015-10-27 | — | — | US | disclosed |
| US-9169259-B2 | Imidazopyridazine compounds | HOFFMANN-LA ROCHE INC. (US) | 2015-10-27 | — | — | US | disclosed |
| US-9169259-B2 | Imidazopyridazine compounds | HOFFMANN-LA ROCHE INC. (US) | 2015-10-27 | — | — | US | disclosed |
| EP-2773645-A1 | IMIDAZOPYRIDAZINE COMPOUNDS | F.HOFFMANN-LA ROCHE AG (CH) | 2014-09-10 | — | — | EP | disclosed |
| WO-2013064445-A1 | IMIDAZOPYRIDAZINE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-05-10 | — | — | WO | disclosed |
| WO-2013064445-A1 | IMIDAZOPYRIDAZINE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-05-10 | — | — | WO | disclosed |
| US-20130109661-A1 | IMIDAZOPYRIDAZINE COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2013-05-02 | — | — | US | disclosed |
| US-20130109661-A1 | IMIDAZOPYRIDAZINE COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2013-05-02 | — | — | US | disclosed |
| US-20130109661-A1 | IMIDAZOPYRIDAZINE COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2013-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130109661-A1 | IMIDAZOPYRIDAZINE COMPOUNDS | SYK, BTK, IRAK4 | SYK 1/4885TAS2R14 3549/4885GRM5 2302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.